

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Berka *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: March 22, 2000

Examiner: To Be Assigned

For: Methods For Monitoring Multiple Gene Expression

VERIFIED STATEMENT UNDER 37 CFR 1.821(f)



Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,

Date: March 22, 2000

A handwritten signature in cursive script, which appears to read 'Robert L. Starnes', is written over a horizontal line.

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
604 Lexington Avenue, Suite 6400
New York, New York 10017
(212) 867-0123